Preclinical studies have shown that blocking CD47 with antibodies or oncolytic viruses can convert TAMs to a pro-inflammatory phenotype and enhance phagocytosis of tumor cells in GBM models55,56. This evidence concerns the gene CD47 and neoplasm.